European Hematology Association, European Myeloma Network Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma
July 09, 2025
July 09, 2025
NORTH HOLLYWOOD, California, July 9 -- The International Myeloma Foundation issued the following news:
* * *
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)
According to a press release from Oncopeptides, "its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN* for patients with relapsed, refracto . . .
* * *
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)
According to a press release from Oncopeptides, "its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN* for patients with relapsed, refracto . . .